Clinical Trials match your criteria
-
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
-
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors
-
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
-
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma
-
RESPONDR ™ TNF EMPOWER
RESPONDR ™ TNF EMPOWER
-
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
-
LONG-TERM STUDY OF TRIPTORELIN IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY
LONG-TERM STUDY OF TRIPTORELIN IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY
-
A RETROSPECTIVE CONTINUATION STUDY IN SMALL FIBER NEUROPATHY IN CHILDREN: PRESENTATION & CLINICAL FEATURES
A RETROSPECTIVE CONTINUATION STUDY IN SMALL FIBER NEUROPATHY IN CHILDREN: PRESENTATION & CLINICAL FEATURES
-
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
-
Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease
